External broker reports(aggregated public sources), Daishin Securities

Daishin Securities

Founded in 1962, Daishin Securities is a leading financial services provider in Korea. Daishin securities does its best to provide high quality financial service and to satisfy the various needs of investors. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Hanmi unveiled phase 3 trial results for next-gen obesity drug efpeglenatide</li><li>Fewer side effects, better affordability; a practical obesity treatment candidate</li><li>Key pipeline results coming into view; we reiterate BUY rating and raise TP</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Hanmi unveiled phase 3 trial results for next-gen obesity drug efpeglenatideFewer side effects, better affordability; a practical obesity treatment candidateKey pipeline results coming into view; we reiterate BUY rating and raise TPContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Hanmi Pharma (128940 KS Oct 28, 2025) - Hunting the KOSPI Obesity Leader